A novel platform to investigate microdosimetry in tumour microenvironment for personalized radioligand therapy

Principal Investigator: 
Prof. Dr. ing. Kuangyu Shi, Department of Nuclear Medicine, Inselspital, Bern University Hospital. For more information, please visit the website.

Co-Investigator: 
Prof. Dr. med. Axel Rominger, Department of Nuclear Medicine, Inselspital, Bern University Hospital. For more information, please visit the website.

Co-Investigator: 
Prof. Dr. Raphael Sznitman, ARTORG Center for Biomedical Engineering Research. For more information, please visit the website.

Co-Investigator: 
Prof. Dr. Roger Schibli, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute. For more information, please visit the website.

Co-Investigator: 
PD Dr. Cristina Müller, Center for Radiopharmaceutical Sciences ETH-PSI-USZ, Paul Scherrer Institute. 

Co-Investigator: 
Dr. Nicholas van der Meulen, Laboratory of Radiochemistry, Paul Scherrer Institute. 

The emerging concept of radioligand therapy has demonstrated great potential in the treatment of metastatic cancer. At least one-third of these patients will, however, experience suboptimal treatment outcomes. This project aims to develop a unique experimental platform for the investigation of microdosimetry to enable a personalized selection of radioisotopes to maximize the treatment outcome of heterogeneous target expression in tumour tissue and related microenvironment. A novel microdosimetry camera will be developed for high-resolution intravital imaging of the distribution of different radioisotopes. After successful completion of this project, the gained in-depth insight into radioligand therapy may boost the development of precision medicine in molecular radiation oncology.